title: [In vitro fertilization in France: economic aspects and influence of the gonadotropin choice (urinary vs. recombinant) on cost].
abstract: OBJECTIVE
  The objective of the study was to make an economic evaluation of in vitro fertilization and to determine the impact of some factors on its cost, particularly the choice between recombinant follicle stimulating hormone (r-FSH) and urinary FSH (u-FSH) for ovarian stimulation.
  
  
  METHODS
  Costs were calculated in a Public Health view, by studying two phases: the stimulation cycle (including down-regulation) and the pregnancy (including the neonatal period). The calculation has included the side effects and the frozen embryos transfers. Economic data came from various sources: the French nomenclature on medical treatments (NGAP), the French drugs dictionary (Vidal) and the French Information system medical plan (PMSI). FSH costs were computed according to the currently marketed products, i.e., Fostimon (Laboratoires Genévrier, Sophia-Antipolis, France) for urinary FSH, and Gonal-F (Laboratoires Serono, Boulogne-Billancourt, France) and Puregon (Laboratoires Organon, Puteaux, France) for recombinant FSH. Two different ways of efficacy between u-FSH and r-FSH were considered for the calculations, those reported in Daya's meta-analysis (3.7% in favour of r-FSH for the clinical pregnancy rate per initiated cycle) and in the only double-blind study (Frydman et al., no difference).
  
  
  RESULTS
  The annual cost of ART reaches approximately 130 million Euros in France, for the cycles only, and 170 million Euros when including the pregnancy costs. Urinary FSH is much cheaper than recombinant FSH. Whereas the number of administered FSH units was higher in u-FSH, this results in a mean lower cost of 500 Euros per cycle (2422 Euros for u-FSH and 2959 Euros for r-FSH). For one complete year, in France, the potential over cost of recombinant products reaches 24 million Euros when considering only the cycles (128.4 vs. 104.0 million Euros) and 24-31 million Euros when pregnancies and babies (neonatal period) are considered (171.4 vs 140.7 and 147.0 million Euros, respectively). The IVF per baby cost can be estimated at 16 463 Euros for r-FSH and at 14 116 Euros (in case of equivalence between the two drugs) to 15 805 Euros (in case of a difference of 3.7% pregnancy per oocyte recovery) for u-FSH.
  
  
  CONCLUSIONS
  This gives Public Health lighting to the choices in the matter of ovulation stimulation. It shows the economic impact of the choice in the FSH type.
authors.affiliation: Inserm U569, hôpital de Bicêtre, 78, avenue du Général-Leclerc, 94272 Le Kremlin-Bicêtre, France. demouzon@vjf.inserm.fr
authors.forename: J
authors.initials: J
authors.lastname: de Mouzon
authors.forename: E
authors.initials: E
authors.lastname: Allavena
authors.forename: C
authors.initials: C
authors.lastname: Schmitt
authors.forename: M
authors.initials: M
authors.lastname: Frappé
mesh_terms: D003365:Costs and Cost Analysis; D016527:Drug Costs; D004624:Embryo Transfer; D005260:Female; D005307:Fertilization in Vitro / Q000191:economics* / Q000379:methods*; D005640:Follicle Stimulating Hormone / Q000008:administration & dosage / Q000191:economics* / Q000652:urine; D005602:France; D006801:Humans; D010062:Ovulation Induction / Q000379:methods; D011247:Pregnancy; D011994:Recombinant Proteins / Q000191:economics
chemical_list: D011994:Recombinant Proteins; D005640:Follicle Stimulating Hormone